4-MeO-PCP

Survey Reveals Older Adults Eager to Get Ahead of Alzheimer's and Other Dementias; Industry Lags

Retrieved on: 
Tuesday, March 21, 2023
Mental Health, Women, Seniors, Men, Health Technology, Other Health, Health, Consumer, General Health, Learning, Alzheimer's disease, 4-MeO-PCP, Disability, Sleep, Dementia, Cancer, Deficit spending, Hope, Risk, Doctor of Philosophy, PCP, Knowledge, Diagnosis, Ageing, FDA, Pharmaceutical industry, Residential care, MD

The survey explored their understanding of dementia and modifiable risk factors; preferences around diagnosis and testing; real-life healthcare experiences in primary care; and likely actions as new treatments become available.

Key Points: 
  • The survey explored their understanding of dementia and modifiable risk factors; preferences around diagnosis and testing; real-life healthcare experiences in primary care; and likely actions as new treatments become available.
  • Survey insights indicate that this need will only grow as new treatments, such as Leqembi™ – recently granted accelerated FDA approval for early-stage Alzheimer’s – come to market.
  • “Dementia is the number one cause of disability in old age, and robs us of our very essence.
  • To access more of the findings, download the Patient Voices on Alzheimer’s and Other Dementias Report here .

The Worldwide Artificial Lift Industry is Expected to Reach $8.7 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 12, 2022
Oil, Gas, Manufacturing, Energy, Machinery, Machine Tools, Metalworking & Metallurgy, Well, Adoption, CAGR, Region, Horizontal, PCP, ESP, Growth, USD, Positive displacement, 4-MeO-PCP, Oil, Vertical

The "Global Artificial Lift Market by Type (ESP, PCP, Rod Lift, Gas Lift), Mechanism (Pump Assisted (Positive Displacement, Dynamic Displacement), Gas Assisted), Well Type (Horizontal, Vertical), Application (Onshore, Offshore) and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Artificial Lift Market by Type (ESP, PCP, Rod Lift, Gas Lift), Mechanism (Pump Assisted (Positive Displacement, Dynamic Displacement), Gas Assisted), Well Type (Horizontal, Vertical), Application (Onshore, Offshore) and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The artificial lift market is projected to grow from an estimated USD 6.9 billion in 2022 to USD 8.7 billion by 2027, at a CAGR of 4.8% during the forecast period.
  • The artificial lift market is segmented by mechanism into pump assisted and gas assisted.
  • By well type, the artificial lift market is segmented into horizontal and vertical wells.

SALIX PHARMACEUTICALS RELEASES LIVER HEALTH ANNUAL TRENDS REPORT UNDERSCORING CHALLENGES IN CARING FOR GROWING CHRONIC LIVER DISEASE AND CIRRHOTIC PATIENT POPULATION

Retrieved on: 
Wednesday, October 12, 2022
Chronic liver disease, LinkedIn, Bausch & Lomb, Liver disease, Gastroenterology, BHC, Publication, Mortality, Centers for Disease Control and Prevention, Medical statistics, National Center for Health Statistics, CEO, Willow, Global health, Hepatic encephalopathy, Adoption, News, Gaps, NYSE, Twitter, Knowledge, Degenerative disease, Center, Company, Ownership, HCPS, Salix Pharmaceuticals, Diagnosis, Stroke, Research, Annual report, 4-MeO-PCP, Systematic review, Form 10-K, Advance for NPs & PAs, Bausch Health, Neurology, HE, Data analysis, Physician, U.S. Securities and Exchange Commission, Marketing, Disease, JD, Edition, Dermatology, Education, Patient, Google, MD, PubMed, CLD, Awareness, Diabetes, Pharmaceutical industry, Health insurance, Dietary supplement, Medicine, IQVIA, QC, Cirrhosis

"This year's report points to a continued rise in mortality from chronic liver disease and cirrhosis, now outpacing diabetes or stroke among those 25-54 years old1.

Key Points: 
  • "This year's report points to a continued rise in mortality from chronic liver disease and cirrhosis, now outpacing diabetes or stroke among those 25-54 years old1.
  • It is our hope the Salix Liver Health Annual Trends Report will increase awareness of this growing public health concern, help bridge the knowledge gap, and provide tools for health care providers that may improve identification and management of the disease."
  • The Salix Liver Health Annual Trends Report is being released in October during Liver Health Awareness Month as part of an effort to equip health care providers with the most current information on liver disease.
  • Select findings from the report include:
    The Liver Health Annual Trends Report on chronic liver disease (CLD) includes information collected from an online survey, qualitative telephone interviews, and secondary research from peer-reviewed publications.

New Spherix Data in Alzheimer's Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk's Semaglutide

Retrieved on: 
Thursday, July 14, 2022
Disease, Rheumatology, Genentech, Moa, Clinical trial, AD, Safety, Gantenerumab, Neurology, Janssen, Dermatology, Eli Lilly and Company, Appetite, Donanemab, Alzheimer's disease, DMT, Patient, Gastroenterology, CMS, Diagnosis, Decision-making, Novo Nordisk, Medicare, Nephrology, FDA, 4-MeO-PCP, Pharmaceutical industry

EXTON, Pa., July 14, 2022 /PRNewswire/ -- Despite multiple high-profile trial failures in early Alzheimer's disease (AD) over the past several years, the pipeline remains robust, with several mechanisms of action (MOAs) being evaluated. Three late-phase anti-amyloid monoclonal antibodies – Biogen/Eisai's lecanemab, Eli Lilly's donanemab, and Genentech's gantenerumab – are expected to read out over the next year and could help shape this evolving market.

Key Points: 
  • Spherix recently surveyed 100 US neurologists and Alzheimer's disease specialists and followed up with ten qualitative interviews to assess the current and future treatment paradigm for early AD patients.
  • Insights, which are included in the Market Dynamix service, uncover referral patterns, diagnostic tools, drivers of treatment selection, and appetite for emerging therapies (among other factors).
  • Neurologists' high interest in tau-targeting mechanisms could bode well for UCB/Roche's bepranemab, Eli Lilly's LY3372689, and Janssen's JNJ-63733657 if clinical data for these drugs prove positive.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Amgen's Aimovig and Eli Lilly's Emgality Feel the Heat From Strong Uptake of Biohaven's Nurtec ODT Among Primary Care Physicians for Migraine Prevention, According to Spherix Global Insights

Retrieved on: 
Tuesday, October 12, 2021
Nephrology, PCP, Topiramate, Migraine, 4-MeO-PCP, EOD, Eli Lilly, CGRP, Teva, Physician, Growth, Mark (given name), Neutralizing antibody, AbbVie, Pressure, Adoption, FDA, Pulse, Calcitonin, Eli Lilly and Company, HCP, Face, Amgen, Patient, Clinical trial, Allergan, Pharmaceutical industry

However, PCP prescribing patterns appear ready to disrupt, rather than merely expand, CGRP prescribing in migraine prevention.

Key Points: 
  • However, PCP prescribing patterns appear ready to disrupt, rather than merely expand, CGRP prescribing in migraine prevention.
  • While these physicians report a relatively low preventive treatment rate among low-frequency episodic migraine patients, the rate more than doubles among high-frequency episodic migraine patients.
  • In addition, there is a concern that patients may run out of Nurtec ODT doses, given payer restrictions on quantity limits.
  • In addition, both Amgen and Eli Lilly appear to be addressing the Nurtec ODT threat head on.